Skip to content
Living Diabetes
  • Home
  • Newly Diagnosed
  • Diabetes Types
    • Type 2 Diabetes
    • Type 1 Diabetes
    • Insulin Resistance
  • Food & Recipes
    • Food
    • Recipes
  • Treatment
    • Medications
    • Weight Loss & Reversal
    • Complications
  • Calculators
  • News
  • Health Guide
  • Home
  • Newly Diagnosed
  • Diabetes Types
    • Type 2 Diabetes
    • Type 1 Diabetes
    • Insulin Resistance
  • Food & Recipes
    • Food
    • Recipes
  • Treatment
    • Medications
    • Weight Loss & Reversal
    • Complications
  • Calculators
  • News
  • Health Guide

type 2 diabetes

Flash Glucose Monitoring and Hospitalizations in Insulin-Treated Type 2 Diabetes: What a New Real-World Study Found

12th August 2026 by Living Diabetes Editorial

A 15,413-person real-world study linked publicly funded flash glucose monitoring with fewer acute diabetes-related hospitalizations, shorter stays, and lower inpatient costs, but its quasi-experimental design cannot prove that monitoring alone caused the improvements.

Categories Blood Glucose Monitoring, News, Type 2 diabetes

Canagliflozin 100 mg vs 300 mg: What a New Kidney and Heart Outcomes Analysis Found

10th August 2026 by Living Diabetes Editorial

A post hoc CANVAS analysis found no clear kidney or cardiovascular advantage for canagliflozin 300 mg over 100 mg, but the findings are hypothesis-generating rather than definitive.

Categories Heart Health, Kidney Health, News, Type 2 diabetes

Evolocumab and Cardiovascular Risk in High-Risk Diabetes: What VESALIUS-CV Found

8th August 2026 by Living Diabetes Editorial

A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with high-risk diabetes, but the results are not a recommendation for everyone with diabetes.

Categories Heart Health, News, Type 2 diabetes

Orforglipron vs Dapagliflozin in Type 2 Diabetes: What the ACHIEVE-2 Trial Found

11th July 2026 by Living Diabetes Editorial

ACHIEVE-2 compared oral orforglipron with dapagliflozin in adults with type 2 diabetes. Learn about HbA1c, weight, side effects, and study limits.

Categories Diabetes Medication, News, Type 2 diabetes

GLP-1 and Incretin Medicines: New Consensus Highlights Nutrition, Muscle, and Mental Health Support

10th July 2026 by Living Diabetes Editorial

A Lancet Diabetes & Endocrinology consensus statement highlights nutrition, muscle, function, GI symptoms, and psychological support during incretin therapy.

Categories Diabetes Medication, News, Weight Loss

Cagrilintide-semaglutide plus basal insulin lowered A1C and weight in adults with type 2 diabetes

5th July 2026 by Living Diabetes Editorial

A Lancet phase 3a trial found cagrilintide-semaglutide added to basal insulin lowered A1C and weight in adults with type 2 diabetes.

Categories Diabetes Medication, News, Obesity, Type 2 diabetes

Heart Health and Type 2 Diabetes: What New Research Says About Modern Diabetes Medications

28th June 2026 by Living Diabetes Editorial

A new review of 133 randomized trials explains how modern type 2 diabetes medication classes may affect heart outcomes.

Categories Diabetes Medication, News, Type 2 diabetes

Semaglutide and Bone Fracture Risk: What People With Type 2 Diabetes Should Know

24th June 2026 by Living Diabetes Editorial

An ENDO 2026 real-world study linked semaglutide with fewer bone fractures than several other weight-loss medicines in adults with type 2 diabetes. The finding is interesting, but it does not prove semaglutide prevents fractures.

Categories Diabetes Medication, Endocrinology, News, Obesity, Type 2 diabetes
Illustration for BMI Calculator for Diabetes Risk (NICE-Aligned, Ethnicity-Aware)

Global Diabetes Trends: Key Statistics and Patient Takeaways

23rd June 2026 by Living Diabetes Editorial

Key WHO diabetes statistics, what the historical data means, why dates matter, and why treatment decisions should stay individualized.

Categories Diabetes Education, News
Illustration for Retatrutide: A New Horizon in Diabetes and Obesity Management

Retatrutide Phase 3 Results: What People With Type 2 Diabetes Should Know

10th June 2026 by Living Diabetes Editorial

Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.

Categories Diabetes Medication, Endocrinology, News, Obesity, Type 2 diabetes
Older posts
Page1 Page2 … Page6 Next →

About Living Diabetes

  • About
  • Editorial Process
  • Sources
  • Glossary
  • Calculators
  • Medical Disclaimer
  • Cookie Policy

Recent Posts

  • Semaglutide Plus Reduced Basal Insulin: What the SUSTAIN OPTIMIZE Trial Found
  • Flash Glucose Monitoring and Hospitalizations in Insulin-Treated Type 2 Diabetes: What a New Real-World Study Found
  • Canagliflozin 100 mg vs 300 mg: What a New Kidney and Heart Outcomes Analysis Found
  • Evolocumab and Cardiovascular Risk in High-Risk Diabetes: What VESALIUS-CV Found
  • Gestational Diabetes and Flash Glucose Monitoring: What a New Randomized Trial Found

Categories

  • Blood Glucose Monitoring
  • Diabetes Complications
  • Diabetes Education
  • Diabetes Medication
  • Diabetes Technology
  • Diet
    • Keto
    • Recipes
      • All Recipes
      • Breakfast
      • Dinner
      • Lunch
  • Endocrinology
    • Thyroid
  • Eye Health
  • Food & Nutrition
  • General
  • Gestational diabetes
  • Heart Health
  • Insulin Resistance
  • Kidney Health
  • Men's Health
  • News
  • Nutrition
  • Obesity
  • Others
  • Physical Activity
  • Summer Travel Safety
  • Type 1 diabetes
  • Type 2 diabetes
  • Weight Loss
Privacy Policy | Terms of Service
© 2026 GeneratePress
  • Home
  • Newly Diagnosed
  • Diabetes Types
    • Type 2 Diabetes
    • Type 1 Diabetes
    • Insulin Resistance
  • Food & Recipes
    • Food
    • Recipes
  • Treatment
    • Medications
    • Weight Loss & Reversal
    • Complications
  • Calculators
  • News
  • Health Guide